In the latest report from CBR Pharma Insights, the new healthcare reform legislation which was finally passed earlier this year is analyzed to provide pharmaceutical & biotech companies with a comprehensive set of tools to support their current and future business plans.
(PRWEB) July 1, 2010 -- After a hotly contested national debate, healthcare reform legislation was passed in the spring of 2010. The legislation contains many long-term benefits for the pharmaceutical industry, but the industry must continue to play an active role in legislation implementation to ensure those benefits are realized.
Through the new laws, there are both wins and losses for the pharmaceutical industry, such as changes effecting Medicare/Medicaid, health insurance coverage expansion & protection, taxation and patent protection. However, on balance most changes hold significant long-term potential for the industry.
While pharma played a very important role in promoting health reform during the debate over change, the work is not done. Many of the greatest potential benefits of the legislation – including extending healthcare coverage to 32 million more Americans – will come down the road. Thus, it is crucial for pharma to remain involved with the healthcare reform roll-out going forward.
Use CBR Pharma Insights' new report, "The New Era of Healthcare Reform - Supporting Revenue Growth through Understanding and Adaptation" to:
About CBR Pharma Insights - CBR Pharma Insights is a strategic market research firm whose mission is to empower companies to make the best business decisions possible through providing them with quality, innovative market research solutions. www.cbrpharmainsights.com
Read the full story at http://www.prweb.com/releases/2010/07HealthcareReform/prweb4211594.htm.
Copyright©2010 Vocus, Inc.
All rights reserved